Barclays analyst Gena Wang maintained a Sell rating on Halozyme (HALO) on February 22 and set a price target of $18. The company’s shares closed on Friday at $16.81.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 21.8% and a 51.7% success rate. Wang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Spark Therapeutics, and Alnylam Pharma.
Halozyme has an analyst consensus of Moderate Buy, with a price target consensus of $20.
See today’s analyst top recommended stocks >>
Based on Halozyme’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $27.85 million. In comparison, last year the company had a net profit of $124 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.
